Both GLP1 and GIP act indirectly on white adipose tissue, whereas GIP directly regulates fat and amino acid metabolism and inflammation within brown adipose tissue
L., Goodband, R
Hausner H et al
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Abdel-Rahman O, Helbling D, Schob O, Eltobgy M, Mohamed H, Schmidt J, et al
The enzyme activity is measured spectrophotometrically by the increased absorbency at 450 nm, corrected from the absorbency at 590 nm, after acidification of formed products